Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | APC Q886* |
Therapy | G007-LK |
Indication/Tumor Type | colorectal cancer |
Response Type | conflicting |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
APC Q886* | colorectal cancer | conflicting | G007-LK | Preclinical - Patient cell culture | Actionable | In a preclinical study, G007-LK inhibited viability of a patient-derived colorectal cancer cell line harboring APC Q886* in culture (PMID: 37968472). | 37968472 |
APC Q886* | colorectal cancer | conflicting | G007-LK | Preclinical | Actionable | In a preclinical study, G007-LK treatment did not alter gene expression pattern or affect growth in mouse intestinal organoids expressing APC Q884* (corresponding to Q886* in human) in culture (PMID: 31337618). | 31337618 |
PubMed Id | Reference Title | Details |
---|---|---|
(31337618) | Distinct Colorectal Cancer-Associated APC Mutations Dictate Response to Tankyrase Inhibition. | Full reference... |
(37968472) | APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells. | Full reference... |